260 related articles for article (PubMed ID: 19436644)
1. Vascular effects of rapid-acting insulin analogs in the diabetic patient: a review.
Fordan S; Raskin P
Vasc Health Risk Manag; 2009; 5(1):225-31. PubMed ID: 19436644
[TBL] [Abstract][Full Text] [Related]
2. Insulin analogs: impact on treatment success, satisfaction, quality of life, and adherence.
Hartman I
Clin Med Res; 2008 Sep; 6(2):54-67. PubMed ID: 18801953
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the effect of insulin glulisine to insulin aspart on breakfast postprandial blood glucose levels in children with type 1 diabetes mellitus on multiple daily injections.
Cemeroglu AP; Kleis L; Wood A; Parkes C; Wood MA; Davis AT
Endocr Pract; 2013; 19(4):614-9. PubMed ID: 23425652
[TBL] [Abstract][Full Text] [Related]
4. Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.
Hermansen K; Colombo M; Storgaard H; ØStergaard A; Kølendorf K; Madsbad S
Diabetes Care; 2002 May; 25(5):883-8. PubMed ID: 11978685
[TBL] [Abstract][Full Text] [Related]
5. Insulin glulisine: efficacy and safety compared with other rapid-acting insulin analogues.
Kamal AD; Bain SC
Expert Opin Drug Saf; 2007 Jan; 6(1):5-7. PubMed ID: 17181446
[TBL] [Abstract][Full Text] [Related]
6. Comparison of daily glucose excursion by continuous glucose monitoring between type 2 diabetic patients receiving preprandial insulin aspart or postprandial insulin glulisine.
Ohta A; Arai K; Nishine A; Sada Y; Kato H; Fukuda H; Asai S; Nagai Y; Katabami T; Tanaka Y
Endocr J; 2013; 60(2):173-7. PubMed ID: 23047542
[TBL] [Abstract][Full Text] [Related]
7. A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.
Plank J; Wutte A; Brunner G; Siebenhofer A; Semlitsch B; Sommer R; Hirschberger S; Pieber TR
Diabetes Care; 2002 Nov; 25(11):2053-7. PubMed ID: 12401756
[TBL] [Abstract][Full Text] [Related]
8. A comparison of the rapid-acting insulin analogue glulisine with lispro and aspart for the pump treatment of patients with type 1 diabetes.
Bramlage P; Tittel SR; Müther S; Reinhart-Steininger B; Haberland H; Khodaverdi S; Zimny S; Ohlenschläger U; Lanzinger S; Haak T
Acta Diabetol; 2022 Nov; 59(11):1453-1460. PubMed ID: 35933650
[TBL] [Abstract][Full Text] [Related]
9. Lower incidence of recorded cardiovascular outcomes in patients with type 2 diabetes using insulin aspart vs. those on human regular insulin: observational evidence from general practices.
Rathmann W; Kostev K
Diabetes Obes Metab; 2013 Apr; 15(4):358-63. PubMed ID: 23137345
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy and safety of rapid-acting insulin analogs, lispro versus aspart, in the treatment of diabetes: a systematic review of randomized controlled trials.
Kapur R; Mittra S; Tonpe G; P A; Raj P; Gudat U; Athalye SN
Expert Opin Biol Ther; 2024 Jun; 24(6):543-561. PubMed ID: 38934226
[TBL] [Abstract][Full Text] [Related]
11. Prandial Insulins: A Person-Centered Choice.
Attri B; Nagendra L; Dutta D; Shetty S; Shaikh S; Kalra S; Bhattacharya S
Curr Diab Rep; 2024 Jun; 24(6):131-145. PubMed ID: 38568467
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
Halimi S; Raskin P; Liebl A; Kawamori R; Fulcher G; Yan G
Clin Ther; 2005; 27 Suppl B():S57-74. PubMed ID: 16519038
[TBL] [Abstract][Full Text] [Related]
13. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients.
Yanagisawa K; Ashihara J; Obara S; Wada N; Takeuchi M; Nishino Y; Maeda S; Ishibashi Y; Yamagishi S
Diabetes Metab Res Rev; 2014 Nov; 30(8):693-700. PubMed ID: 24639403
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of insulin glulisine in Japanese patients with type 1 diabetes mellitus.
Kawamori R; Kadowaki T; Ishii H; Iwasaki M; Iwamoto Y
Diabetes Obes Metab; 2009 Sep; 11(9):891-9. PubMed ID: 19614947
[TBL] [Abstract][Full Text] [Related]
15. The insulin analog glargine during an unplanned pregnancy.
Cechurová D; Lacigová S; Jankovec Z; Haladová I; Zourek M; Krcma M; Rusavý Z; Turek J
Wien Klin Wochenschr; 2006 Oct; 118(19-20):619-20. PubMed ID: 17136338
[No Abstract] [Full Text] [Related]
16. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes.
Pfützner A; Küstner E; Forst T; Schulze-Schleppinghoff B; Trautmann ME; Haslbeck M; Schatz H; Beyer J
Exp Clin Endocrinol Diabetes; 1996; 104(1):25-30. PubMed ID: 8750567
[TBL] [Abstract][Full Text] [Related]
17. Use of a novel double-antibody technique to describe the pharmacokinetics of rapid-acting insulin analogs.
Lindström T; Hedman CA; Arnqvist HJ
Diabetes Care; 2002 Jun; 25(6):1049-54. PubMed ID: 12032113
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of insulin lispro in combination with NPH human insulin twice per day in patients with insulin-dependent or non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group.
Vignati L; Anderson JH; Iversen PW
Clin Ther; 1997; 19(6):1408-21. PubMed ID: 9444449
[TBL] [Abstract][Full Text] [Related]
19. Defining the role of insulin lispro in the management of postprandial hyperglycaemia in patients with type 2 diabetes mellitus.
Giugliano D; Ceriello A; Razzoli E; Esposito K
Clin Drug Investig; 2008; 28(4):199-210. PubMed ID: 18345710
[TBL] [Abstract][Full Text] [Related]
20. Insulin lispro (Humalog), a novel fast-acting insulin analogue for the treatment of diabetes mellitus: overview of pharmacological and clinical data.
Hermans MP; Nobels FR; De Leeuw I
Acta Clin Belg; 1999 Oct; 54(5):233-40. PubMed ID: 10555380
[No Abstract] [Full Text] [Related]
[Next] [New Search]
